Pentostatin as rescue therapy for glucocorticoid-refractory acute and chronic graft-versus-host disease

Annals of Transplantation

Volumn 15, Issue 4, 2010, Pages 21-29

  Pidala, Joseph ^a,b   Kim, Jongphil ^a   Roman Diaz, Jaime ^a   Shapiro, Jamie ^a,b   Nishihori, Taiga ^a,b   Bookout, Ryan ^a,b   Anasetti, Claudio ^a,b   Kharfan Dabaja, Mohamed A ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Acute graft versus host disease; Chronic graft versus host disease; Glucocorticoids; Pentostatin

Indexed keywords

GLUCOCORTICOID; PENTOSTATIN;

ACUTE GRAFT VERSUS HOST DISEASE; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; DRUG DOSE REDUCTION; HUMAN; IMMUNOTHERAPY; INFECTIOUS COMPLICATION; NEPHROTOXICITY; OVERALL SURVIVAL; REMISSION; TREATMENT RESPONSE;

ACUTE DISEASE; ADENOSINE DEAMINASE INHIBITORS; CHRONIC DISEASE; DRUG RESISTANCE; GLUCOCORTICOIDS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; PENTOSTATIN; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 78651251952     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Chao NJ, Chen BJ: Prophylaxis and treatment of acute graft-versus-host disease. Semin Hematol, 2006; 43: 32-41
2. Deeg HJ: How I treat refractory acute GVHD. Blood, 2007; 109: 4119-4126
3. Filipovich AH: Diagnosis and manifestations of chronic graft-versus-host disease. Best Pract Res Clin Haematol, 2008; 21: 251-257
4. Martin PJ, Schoch G, Fisher L et al: A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood, 1990; 76: 1464-1472
5. Vogelsang GB: How I treat chronic graft-versushost disease. Blood, 2001; 97: 1196-1201
6. MacMillan ML, Weisdorf DJ, Wagner JE et al: Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant, 2002; 8: 387-394
7. Anasetti C, Hansen JA, Waldmann TA et al: Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood, 1994; 84: 1320-1327
8. Arai S, Margolis J, Zahurak M et al: Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant, 2002; 8: 155-160
9. Benito AI, Furlong T, Martin PJ et al: Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation, 2001; 72: 1924-1929
10. Carpenter PA, Lowder J, Johnston L et al: A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant, 2005; 11: 465-471
11. Deeg HJ, Blazar BR, Bolwell BJ et al: Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. Blood, 2001; 98: 2052-2058
12. Greinix HT, Volc-Platzer B, Kalhs P et al: Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study. Blood, 2000; 96: 2426-2431
13. Ho VT, Zahrieh D, Hochberg E et al: Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood, 2004; 104: 1224-1226
14. Le Blanc K, Frassoni F, Ball L et al: Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet, 2008; 371: 1579-1586
15. Martinez C, Solano C, Ferra C et al: Alemtuzumab as treatment of steroid-refractory acute graftversus-host disease: results of a phase II study. Biol Blood Marrow Transplant, 2009; 15: 639-642
16. Pidala J, Kim J, Field T et al: Infliximab for managing steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant, 2009; 15: 1116-1121
17. Pidala J, Kim J, Perkins J et al: Mycophenolate mofetil for the management of steroid-refractory acute graft vs host disease. Bone Marrow Transplant, 2010; 45(5): 919-924
18. Lee SJ, Flowers ME: Recognizing and managing chronic graft-versus-host disease. Hematology Am Soc Hematol Educ Program, 2008: 134-141
19. Filipovich AH, Weisdorf D, Pavletic S et al: National Institutes of Health consensus development project on criteria for clinical trials in chronic graftversus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant, 2005; 11: 945-956
20. Fraser CJ, Bhatia S, Ness K et al: Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study. Blood, 2006; 108: 2867-2873
21. Lee SJ, Kim HT, Ho VT et al: Quality of life associated with acute and chronic graft-versus-host disease. Bone Marrow Transplant, 2006; 38: 305-310
22. Syrjala KL, Chapko MK, Vitaliano PP et al: Recovery after allogeneic marrow transplantation: prospective study of predictors of long-term physical and psychosocial functioning. Bone Marrow Transplant, 1993; 11: 319-327
23. Worel N, Biener D, Kalhs P et al: Long-term outcome and quality of life of patients who are alive and in complete remission more than two years after allogeneic and syngeneic stem cell transplantation. Bone Marrow Transplant, 2002; 30: 619-626
24. Martin PJ, Storer BE, Rowley SD et al: Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood, 2009; 113: 5074-5082
25. Akpek G, Lee SM, Anders V, Vogelsang GB: A highdose pulse steroid regimen for controlling active chronic graft-versus-host disease. Biol Blood Marrow Transplant, 2001; 7: 495-502
26. Browne PV, Weisdorf DJ, DeFor T et al: Response to thalidomide therapy in refractory chronic graftversus-host disease. Bone Marrow Transplant, 2000; 26: 865-869
27. Busca A, Locatelli F, Marmont F et al: Response to mycophenolate mofetil therapy in refractory chronic graft-versus-host disease. Haematologica, 2003; 88: 837-839
28. Carnevale-Schianca F, Martin P, Sullivan K et al: Changing from cyclosporine to tacrolimus as salvage therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant, 2000; 6: 613-620
29. Couriel DR, Hosing C, Saliba R et al: Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood, 2006; 107: 3074-3080
30. Couriel DR, Saliba R, Escalon MP et al: Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versushost disease. Br J Haematol, 2005; 130: 409-417
31. Cutler C, Miklos D, Kim HT et al: Rituximab for steroid-refractory chronic graft-versus-host disease. Blood, 2006; 108: 756-762
32. Flowers ME, Apperley JF, van Besien K et al: A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood, 2008; 112: 2667-2674
33. Jacobsohn DA, Chen AR, Zahurak M et al: Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease. J Clin Oncol, 2007; 25: 4255-4261
34. Johnston LJ, Brown J, Shizuru JA et al: Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant, 2005; 11: 47-55
35. Kulkarni S, Powles R, Sirohi B et al: Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease. Bone Marrow Transplant, 2003; 32: 165-170
36. Lopez F, Parker P, Nademanee A et al: Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant, 2005; 11: 307-313
37. Mookerjee B, Altomonte V, Vogelsang G: Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus. Bone Marrow Transplant, 1999; 24: 517-520
38. Parker PM, Chao N, Nademanee A et al: Thalidomide as salvage therapy for chronic graft-versushost disease. Blood, 1995; 86: 3604-3609
39. Scarisbrick JJ, Taylor P, Holtick U et al: U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease. Br J Dermatol, 2008; 158: 659-678
40. Tzakis AG, Abu-Elmagd K, Fung JJ et al: FK 506 rescue in chronic graft-versus-host-disease after bone marrow transplantation. Transplant Proc, 1991; 23: 3225-3227
41. Zaja F, Bacigalupo A, Patriarca F et al: Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant, 2007; 40: 273-277
42. Bolanos-Meade J, Jacobsohn DA, Margolis J et al: Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol, 2005; 23: 2661-2668
43. Schmitt T, Luft T, Hegenbart U et al: Pentostatin for treatment of steroid-refractory acute GVHD: a retrospective single-center analysis. Bone Marrow Transplant, 2010; [Epub ahead of print]
44. Przepiorka D, Weisdorf D, Martin P et al: 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant, 1995; 15: 825-828
45. Pavletic SZ, Martin P, Lee SJ et al: Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant, 2006; 12: 252-266